Redx Pharma is a UK-based pharmaceutical company developing new drug candidates using the broad-based potential of its innovative Redox Switch™ platform.
Our novel approach, which has seen validation across 11 different therapeutic classes, has allowed Redx Pharma to generate an enviable pipeline of candidate programs which are characterised by demonstrably lower risk and greater speed into development and providing a flow of licensing opportunities that is filling the global pharma productivity gap.
Liverpool-based drug discovery and development company Redx Pharma is to open a new research and development facility at AstraZeneca's Alderley Park site in Cheshire.
The new venture, Redx Anti-Infectives Ltd, will create 119 high value science jobs at the site, establishing a new team to develop drugs combatting resistance to antibiotics and new medicines to tackle viral infections. A particular focus will be hard to treat infections. These include the growing threat of drug resistant superbugs like MRSA, as well as conditions such as influenza, Hepatitis C and HIV. A further 28 specialist jobs are expected to be created within the wider supply chain.
